Biological E's protein sub-unit vaccine roll out likely in November

Firm plans to make a billion annual doses of the vaccine apart from 600 million J&J doses a year

The much-awaited Biological E protein sub-unit Covid-19 vaccine Corbevax is likely to be rolled out by November end, the company’s senior official said on Monday.

Mahima Datla, managing director, Biological E, said the firm was getting ready with 100 million doses for the launch. “Cobevax is in phase-3 trials. We are likely to complete all the studies by end of November which is when we are expecting a licence (from the drug regulator). The license for children should follow one month later. The study in children is underway as well," she said.

She was speaking to reporters at the sidelines